Project Grant R01HL181500
- This federal Project Grant award in the amount of $1,428,186.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Massachusetts. The project aims to investigate the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans, which has implications for understanding the early...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $190,491 to Beth Israel Deaconess Medical Center, Inc. to conduct research on plasma protein markers of the blood pressure response during exercise and their relation to incident hypertension and cardiovascular disease. The project aims to identify circulating proteins associated with exercise blood pressure that could serve as predictive markers for future...
- This federal Project Grant award for $743,388, awarded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the mechanisms by which sleep loss and circadian misalignment contribute to insulin resistance and the development of Type 2 diabetes mellitus. The award will fund two randomized controlled trials with 48 adult participants to characterize the role of cortisol rhythms and downstream metabolomic and endocrine...
- This $326,797 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to identify proteomic (protein-based) biomarkers that can predict risk of cognitive impairment in individuals with type 2 diabetes. The primary goal is to use proteomic analyses to discover plasma protein differences and networks associated with newly diagnosed mild cognitive impairment in this population. The project will also examine how these proteins relate to preclinical...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Inc.) to assess the impact of improving cardiovascular disease (CVD) care for adults with diagnosed diabetes across diverse global settings. The project, led by Dr. Jennifer Manne-Goehler and an interdisciplinary team, aims to develop the PREDICT-DM global...
- This federal Project Grant award of $813,511 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the structural basis and functional consequences of thermogenic mitochondrial respiratory complexes assembly in the context of obesity and type 2 diabetes. The research aims to...
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- This federal Project Grant award for $603,632, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, aims to define the role of the PLA2G12B protein in regulating the assembly, plasma levels, metabolism, and cardiovascular disease risk of apolipoprotein B (apoB)-containing lipoproteins. The primary grantee, The Johns Hopkins University, will leverage novel tools to investigate how...
- This Project Grant award of $784,362.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., will support research investigating the role of body composition, coronary microvascular dysfunction, and heart failure with preserved ejection fraction in characterizing adverse cardiometabolic disease phenotypes. The research aims to leverage novel imaging technologies to identify mechanisms of...
- This $2,782,476 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) supports research to determine the molecular mechanisms underlying pancreatic beta cell response to metabolic stress, a key factor in the development of type 2 diabetes. The 4-year project aims to leverage in vitro human beta cell models, single-cell transcriptomic analyses, and targeted drug screening to delineate the dynamic chromatin and transcriptomic changes that...
This $693,964 federal Project Grant award from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports a multi-year research project at Beth Israel Deaconess Medical Center, Inc. to identify novel protein biomarkers of youth-onset type 2 diabetes (YOT2D). The project will use comprehensive proteomics profiling of plasma samples from a cohort of youths with T2D and adults with T2D to elucidate biological pathways contributing to the rapid disease progression seen in YOT2D. The identified novel biomarkers have the potential to serve as prognostic markers and therapeutic targets to improve YOT2D outcomes. The project will leverage data from two seminal YOT2D cohorts and compare the findings to an adult T2D cohort from the Multi-Ethnic Study of Atherosclerosis. The award commenced on Sep 15, 2025 and is scheduled for completion on Jun 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $694.0k | 9/12/25 |